286 related articles for article (PubMed ID: 33115537)
21. Phosphorylated and cleaved TDP-43 in ALS, FTLD and other neurodegenerative disorders and in cellular models of TDP-43 proteinopathy.
Arai T; Hasegawa M; Nonoka T; Kametani F; Yamashita M; Hosokawa M; Niizato K; Tsuchiya K; Kobayashi Z; Ikeda K; Yoshida M; Onaya M; Fujishiro H; Akiyama H
Neuropathology; 2010 Apr; 30(2):170-81. PubMed ID: 20102522
[TBL] [Abstract][Full Text] [Related]
22. Functional recovery in new mouse models of ALS/FTLD after clearance of pathological cytoplasmic TDP-43.
Walker AK; Spiller KJ; Ge G; Zheng A; Xu Y; Zhou M; Tripathy K; Kwong LK; Trojanowski JQ; Lee VM
Acta Neuropathol; 2015 Nov; 130(5):643-60. PubMed ID: 26197969
[TBL] [Abstract][Full Text] [Related]
23. [Conjoint pathological cascades mediated by RNA-binding proteins, TDP-43, FUS and ataxin-2].
Ito D
Rinsho Shinkeigaku; 2012; 52(11):1221-3. PubMed ID: 23196570
[TBL] [Abstract][Full Text] [Related]
24. Antibody against TDP-43 phosphorylated at serine 375 suggests conformational differences of TDP-43 aggregates among FTLD-TDP subtypes.
Neumann M; Frick P; Paron F; Kosten J; Buratti E; Mackenzie IR
Acta Neuropathol; 2020 Nov; 140(5):645-658. PubMed ID: 32778941
[TBL] [Abstract][Full Text] [Related]
25. TDP-43 levels in the brain tissue of ALS cases with and without
Yang Y; Halliday GM; Kiernan MC; Tan RH
Neurology; 2019 Nov; 93(19):e1748-e1755. PubMed ID: 31619481
[TBL] [Abstract][Full Text] [Related]
26. TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration.
Wils H; Kleinberger G; Janssens J; Pereson S; Joris G; Cuijt I; Smits V; Ceuterick-de Groote C; Van Broeckhoven C; Kumar-Singh S
Proc Natl Acad Sci U S A; 2010 Feb; 107(8):3858-63. PubMed ID: 20133711
[TBL] [Abstract][Full Text] [Related]
27. Optineurin inclusions occur in a minority of TDP-43 positive ALS and FTLD-TDP cases and are rarely observed in other neurodegenerative disorders.
Hortobágyi T; Troakes C; Nishimura AL; Vance C; van Swieten JC; Seelaar H; King A; Al-Sarraj S; Rogelj B; Shaw CE
Acta Neuropathol; 2011 Apr; 121(4):519-27. PubMed ID: 21360076
[TBL] [Abstract][Full Text] [Related]
28. Disease animal models of TDP-43 proteinopathy and their pre-clinical applications.
Liu YC; Chiang PM; Tsai KJ
Int J Mol Sci; 2013 Oct; 14(10):20079-111. PubMed ID: 24113586
[TBL] [Abstract][Full Text] [Related]
29. Developmentally Regulated RNA-binding Protein 1 (Drb1)/RNA-binding Motif Protein 45 (RBM45), a Nuclear-Cytoplasmic Trafficking Protein, Forms TAR DNA-binding Protein 43 (TDP-43)-mediated Cytoplasmic Aggregates.
Mashiko T; Sakashita E; Kasashima K; Tominaga K; Kuroiwa K; Nozaki Y; Matsuura T; Hamamoto T; Endo H
J Biol Chem; 2016 Jul; 291(29):14996-5007. PubMed ID: 27226551
[TBL] [Abstract][Full Text] [Related]
30. Low molecular weight species of TDP-43 generated by abnormal splicing form inclusions in amyotrophic lateral sclerosis and result in motor neuron death.
Xiao S; Sanelli T; Chiang H; Sun Y; Chakrabartty A; Keith J; Rogaeva E; Zinman L; Robertson J
Acta Neuropathol; 2015 Jul; 130(1):49-61. PubMed ID: 25788357
[TBL] [Abstract][Full Text] [Related]
31. Pathway from TDP-43-Related Pathology to Neuronal Dysfunction in Amyotrophic Lateral Sclerosis and Frontotemporal Lobar Degeneration.
Riku Y; Seilhean D; Duyckaerts C; Boluda S; Iguchi Y; Ishigaki S; Iwasaki Y; Yoshida M; Sobue G; Katsuno M
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33917673
[TBL] [Abstract][Full Text] [Related]
32. Enrichment of C-terminal fragments in TAR DNA-binding protein-43 cytoplasmic inclusions in brain but not in spinal cord of frontotemporal lobar degeneration and amyotrophic lateral sclerosis.
Igaz LM; Kwong LK; Xu Y; Truax AC; Uryu K; Neumann M; Clark CM; Elman LB; Miller BL; Grossman M; McCluskey LF; Trojanowski JQ; Lee VM
Am J Pathol; 2008 Jul; 173(1):182-94. PubMed ID: 18535185
[TBL] [Abstract][Full Text] [Related]
33. [Intracellular seeded aggregation of TDP-43].
Nonaka T; Hasegawa M
Rinsho Shinkeigaku; 2012; 52(11):1056-8. PubMed ID: 23196514
[TBL] [Abstract][Full Text] [Related]
34. Quantification of the Relative Contributions of Loss-of-function and Gain-of-function Mechanisms in TAR DNA-binding Protein 43 (TDP-43) Proteinopathies.
Cascella R; Capitini C; Fani G; Dobson CM; Cecchi C; Chiti F
J Biol Chem; 2016 Sep; 291(37):19437-48. PubMed ID: 27445339
[TBL] [Abstract][Full Text] [Related]
35. Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis.
Hasegawa M; Arai T; Nonaka T; Kametani F; Yoshida M; Hashizume Y; Beach TG; Buratti E; Baralle F; Morita M; Nakano I; Oda T; Tsuchiya K; Akiyama H
Ann Neurol; 2008 Jul; 64(1):60-70. PubMed ID: 18546284
[TBL] [Abstract][Full Text] [Related]
36. Laminar distribution of the pathological changes in sporadic frontotemporal lobar degeneration with transactive response (TAR) DNA-binding protein of 43 kDa (TDP-43) proteinopathy: a quantitative study using polynomial curve fitting.
Armstrong RA; Hamilton RL; Mackenzie IR; Hedreen J; Cairns NJ
Neuropathol Appl Neurobiol; 2013 Jun; 39(4):335-47. PubMed ID: 22804696
[TBL] [Abstract][Full Text] [Related]
37. A quantitative study of the neuropathology of 32 sporadic and familial cases of frontotemporal lobar degeneration with TDP-43 proteinopathy (FTLD-TDP).
Armstrong RA; Carter D; Cairns NJ
Neuropathol Appl Neurobiol; 2012 Feb; 38(1):25-38. PubMed ID: 21696412
[TBL] [Abstract][Full Text] [Related]
38. A 43-kDa TDP-43 species is present in aggregates associated with frontotemporal lobar degeneration.
Bosque PJ; Boyer PJ; Mishra P
PLoS One; 2013; 8(5):e62301. PubMed ID: 23704877
[TBL] [Abstract][Full Text] [Related]
39. [FTLD/ALS as TDP-43 proteinopathies].
Ishihara T; Ariizumi Y; Shiga A; Yokoseki A; Sato T; Toyoshima Y; Kakita A; Takahashi H; Nishizawa M; Onodera O
Rinsho Shinkeigaku; 2010 Nov; 50(11):1022-4. PubMed ID: 21921552
[TBL] [Abstract][Full Text] [Related]
40. Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice.
Igaz LM; Kwong LK; Lee EB; Chen-Plotkin A; Swanson E; Unger T; Malunda J; Xu Y; Winton MJ; Trojanowski JQ; Lee VM
J Clin Invest; 2011 Feb; 121(2):726-38. PubMed ID: 21206091
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
